| 1 |
Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia[J]. Eur Respir J, 2023, 61(4): 2200735.
|
| 2 |
Teh BW, Mikulska M, Averbuch D, et al. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients[J] . Lancet Infect Dis, 2024, 24(1): e59-e68.
|
| 3 |
Inke RK, Oliver F, Gesine H, et al. What is precision medicine？[J]. Eur Respir J, 2017, 50(4): 1700391.
|
| 4 |
中华医学会呼吸病学分会. 下呼吸道感染宏基因组二代测序报告临床解读路径专家共识[J] . 中华结核和呼吸杂志，2023, 46(4): 322-335.
|
| 5 |
Markussen DL, Serigstad S, Ritz C, et al. Diagnostic stewardship in community-acquired pneumonia with syndromic molecular testing: A randomized clinical trial[J]. JAMA Netw Open, 2024, 7(3): e240830.
|
| 6 |
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J] . Lancet, 2018, 392(10159): 1736-1788.
|
| 7 |
GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021[J] . Lancet Infect Dis, 2024, 24(9): 974-1002.
|
| 8 |
Niederman MS, Torres A. Severe community-acquired pneumonia[J]. Eur Respir Rev, 2022, 31(166): 220123.
|
| 9 |
Meyer NJ, Gattinoni L, Calfee CS, et al. Acute respiratory distress syndrome[J] . Lancet, 2021, 398(10300): 622-637.
|
| 10 |
刘大为. 一个值得深思的问题：重症治疗是病情导向抑或治疗目标导向[J]. 中华内科杂志，2022, 61(6): 607-610.
|
| 11 |
中华医学会，中华医学会临床药学分会，中华医学会杂志社，等. 成人社区获得性肺炎基层合理用药指南[J]. 中华全科医师杂志，2020, 19(9): 783-791.
|
| 12 |
袁喆，钱克莉，王忠杰. 耐碳青霉烯肺炎克雷伯菌耐药机制及治疗策略[J]. 西南医科大学学报，2024, 47(2): 104-110.
|
| 13 |
Gadsby NJ, Musher DM. The microbial etiology of community-acquired pneumonia in adults: from Classical bacteriology to host transcriptional signatures[J] . Clin Microbiol Rev, 2022, 35(4): e0001522.
|
| 14 |
Fagerli K, Ulziibayar M, Suuri B, et al. Epidemiology of pneumonia in hospitalized adults ≥18 years old in four districts of Ulaanbaatar, Mongolia, 2015-2019[J] . Lancet Reg Health West Pac, 2022, 30: 100591.
|
| 15 |
Barbier F, Buetti N, Dupuis C, et al. Prognostic impact of early appropriate antimicrobial therapy in critically Ⅲ patients with nosocomial pneumonia due to gram-negative pathogens: A Multicenter Cohort Study[J] . Crit Care Med, 2025, 53(5): e1066-e1079.
|
| 16 |
Kim C, Holm M, Frost I, et al. Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study[J]. BMJ Glob Health, 2023, 8(7): e011341.
|
| 17 |
中华医学会细菌感染与耐药防治分会. 呼吸系统感染中宏基因组测序技术临床应用与结果解读专家共识[J]. 中华临床感染病杂志，2022, 15(2): 90-102.
|
| 18 |
中国医疗保健国际交流促进会临床微生物学分会. 靶向高通量测序在感染性疾病中应用与实践专家共识[J]. 中华医学杂志，2024, 104(48): 4375-4383.
|
| 19 |
姜宁，龙秋月，郑雅莉，等. 社区获得性肺炎流行病学与病原学及其治疗进展[J]. 中华预防医学杂志，2023, 57(1): 91-99.
|
| 20 |
Liakopoulos A, Aulin LBS, Buffoni M, et al. Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution[J]. Proc Natl Acad Sci U S A, 2022, 119(18): e2121768119.
|
| 21 |
Abdalla JS, Albarrak M, Alhasawi A, et al. Narrative review of the epidemiology of hospital-acquired pneumonia and ventilator-associated pneumonia in gulf cooperation council countries[J] . Infect Dis Ther, 2023, 12(7): 1741-1773.
|
| 22 |
陈思缄，詹庆元，黄琳娜，等. 流感病毒继发肺部金黄色葡萄球菌的感染机制[J] . 中华结核和呼吸杂志，2023, 46(6): 646-650.
|
| 23 |
刘玉强，侯春霞，成亚东，等. 不同抗生素治疗MRSA感染性肺炎的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(1): 171-175.
|
| 24 |
Lu H, Zhang K, Zhang W, et al. Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia[J]. Trends Biotechnol, 2025, 43(9): 2276-2303.
|
| 25 |
Yin YY, Zhao CJ, Li HN, et al. Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China[J] . Eur J Clin Microbiol Infect Dis, 2021, 40(4): 683-690.
|
| 26 |
中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022年版)[J]. 中华结核和呼吸杂志，2022, 45(8): 739-752.
|
| 27 |
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of america guidance on the treatment of extended-spectrum β-iactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)[J] . Clin Infect Dis, 2022, 75(2): 187-212.
|
| 28 |
Tan X, Huang YQ, Rana A, et al. Optimization of an in vitro pseudomonas aeruginosa biofilm model to examine antibiotic pharmacodynamics at the air-liquid interface[J]. NPJ Biofilms Microbiomes, 2024, 10(1): 16.
|
| 29 |
中国医药教育协会感染疾病专业委员会(IDSC). 多黏菌素类药物雾化吸入治疗下呼吸道多重耐药革兰阴性菌感染中国专家共识(2024年版)[J]. 中华临床感染病杂志，2024, 17(5): 353-366.
|
| 30 |
Albin OR, Kaye KS, McCreary EK, et al. Less is more Antibiotic treatment duration in pseudomonas aeruginosa ventilator-associated pneumonia[J]. Clin Infect Dis, 2023, 76(4): 745-749.
|
| 31 |
Jason MP, Zhou Y, Hemanth K, et al. Burden of illness in carbapenem-resistant acinetobacter baumannii infections in US hospitals between 2014 and 2019[J] . BMC Infect Dis, 2022, 22(1): 36.
|
| 32 |
Wahid B, Tiwana MS, Ali A. Revolutionising infection control: building the next generation of phage banks[J]. Drug Resist Updat, 2024, 77: 101143.
|
| 33 |
中国研究型医院学会危重医学专业委员会，中国研究型医院学会感染性疾病循证与转化专业委员会. 多黏菌素临床应用中国专家共识[J]. 中华危重病急救医学，2019, 31(10): 1194-1198.
|
| 34 |
John TM , Deshpande A, Brizendine K, et al. Epidemiology and outcomes of community-acquired escherichia coli pneumonia[J] .Open Forum Infect Dis, 2022, 9(1): ofab597.
|
| 35 |
Assefa M. Multi-drug resistant gram-negative bacterial pneumonia: Etiology, risk factors, and drug resistance patterns[J] . Pneumonia (Nathan), 2022, 14(1): 4.
|
| 36 |
Celebi D, Aydin E, Rakici E, et al. Evaluation of presence of clone ST131 and biofilm formation in ESBL producing and non-producing Escherichia coli strains[J] . Mol Biol Rep, 2023, 50(7): 5949-5956.
|
| 37 |
Lima AH, van der Kamp MW. Insights into the enhanced ceftazidime hydrolysis by ent385 ampC β-Lactamase from multiscale simulations[J]. ACS Catal, 2025, 15(13): 11739- 11748.
|
| 38 |
Andre CK, Mark LM, Michael K, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society[J] . Clin Infect Dis, 2016, 63(5): e61-e111.
|
| 39 |
孔海芳，胡志东. 高毒力肺炎克雷伯菌流行病学特征及其致病性毒力因子[J]. 国际流行病学传染病学杂志，2021, 48(1): 80-83.
|
| 40 |
Sree RA, Gupta A, Gupta N, et al. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India[J]. Infection, 2024, 52(2): 429-437.
|
| 41 |
Tavleen KJ, Ritesh A, Pei YT, et al. Fungal lung disease[J]. Eur Respir J, 2024, 64(5): 2400803.
|
| 42 |
Azoulay E, Russell L，Van de Louw Andry, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J] . Intensive Care Med, 2020, 46: 298-314.
|
| 43 |
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive funga disease from the european organization for research and treatment of cancer and the Mycoses study group education and research consortium[J]. Clin Infect Dis, 2020, 71(6): 1367-1376.
|
| 44 |
Nagai T, Matsui H, Fujioka H, et al. Low-dose vs. conventional-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in patients not infected with HIV: A multicenter, retrospective observational cohort study[J]. Chest, 2024, 165(1): 58-67.
|
| 45 |
冯佳佳，孔维华，林丽开. 中国真菌感染管理政策解读[J]. 中华实用儿科临床杂志，2024, 39(1): 7-9.
|
| 46 |
Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses[J]. Lancet, 2020, 395(10235): 1517-1520.
|
| 47 |
Febbo J, Revels J, Ketai L. Viral Pneumonias[J]. Infect Dis Clin North Am, 2024, 38(1): 163-182.
|